Proactive Investors - Run By Investors For Investors

Breakfast News - Sativa Investments, Perfomatrix PLC,Action Hotels and more...

Breakfast News -  Sativa Investments, Perfomatrix PLC,Action Hotels and more...

Small Cap Breakfast

Set menu

AIM:

Total number of AIM Companies (Incl Susp):

948*

Total number of AIM Companies trading:

898*

*as at close of business 20 March 2018

 

Standard List**  of Main Market:

Total number of Standard List Companies

(Incl Susp):

136*

Total number of Standard List Companies trading:

123*

*as at close of business 20March 2018

 

NEX Growth Market:

Total number of NEX Growth Market Companies (Incl Susp):

88*

Total number of NEX Growth Market Companies trading:

82*               

*as at close of business 20March 2018 

                                *A corporate client of Hybridan LLP

 **  Standard Listing as defined by Hybridan LLP to be a business with strictly operational activity

                            

Dish of the day

No Joiners Today

Off the menu   

MayAir has left AIM after being acquired by Poly Glorious

             

What’s cooking in the IPO kitchen?

NEX Exchange

Sativa Investments Due 29 Mar. Raising £1m at 1p. Mkt cap £4m.  Investment Vehicle  for investment opportunities and acquisitions in companies which are well-placed to take advantage of the dynamic regulatory environment surrounding legal Medicinal Cannabis.

AIM

Kore Potash— advanced stage mineral exploration and development company whose primary asset is its interest in the Sintoukola Project, a potash project located in the Republic of Congo. ) Measured, Indicated and Inferred Mineral Resource of 5,953Mt at an average grade of 22.0% KCl. Offer TBA. Due end March.

Perfomatrix PLC, a global end to end Performance Marketing technology and services company headquartered in the UK, is looking to join AIM in early April 2018, offer TBC

Crusader Resources, an ASX-listed public company incorporated in Australia, which is primarily focused on the exploration and development of gold assets in Brazil. Offer TBC, expected late March.

SimplyBiz, a Financial Services Firm, looking to join AIM raising £30m via placing and £34.6m via a sale of existing ordinary shares at 170p giving a market cap of £130m. Expected 4 April

Bacanora Lithium—Readmission. No new money. Mkt cap £140m. Due 21 March. the new holding company for Bacanora Minerals Ltd 

Core Industrial REIT—established to invest in Irish-based industrial properties, predominantly located in the Greater Dublin Area. Vendor placing and new funds to a total of €225m, Target gross proceeds €207m. Expected Mid March

Polarean  - Medical drug-device combination company operating in the high resolution medical imaging market. Offer TBC. Due 26 March

 

Main Market Premium Listing

Gore Street Energy Storage Fund—Seeking to raise £100m for the purposes of investment in a diversified portfolio of utility scale energy storage projects.  Due 12 April.

Broker and investment platform operator AJ Bell reported to be considering London float with a valuation at £50m.

                              

Breakfast buffet

Integrated Diagnostic Holdings (LON:IDHC) $4.325 $655m

FYDec17 results from the consumer healthcare company with operations in Egypt, Jordan, Sudan and Nigeria. Revenues increased 29% to EGP 1,514m in 2017 from EGP 1,171m in 2016, driven by a combination of better pricing, favourable currency translation and higher volumes. Net profit grew 44% year-on-year to EGP 384m in 2017 versus EGP 267m in 2016, benefiting from increased interest income and a lower foreign exchange loss.  Recommended final dividend of $0.16  per share, equivalent to $24m in total, compared with $0.14 per share, equivalent to US$ 21 million in total in 2016.

“We enter 2018 in a strong financial position and well positioned as a leading consumer healthcare company in the Middle East and Africa. In the coming year, we will continue to focus on expanding our geographies as well as on the process of integrating our new Nigerian operations”. FYDec18E EGP 1.8bn, PBT EGP 708m.

 

Action Hotels (LON:AHCG) 19.25p £28.4m

The “owner, developer and asset manager of branded three and four-star hotels in the Middle East and Australia,  announced the opening of Novotel Melbourne South Wharf hotel, ahead of schedule

The 347-room flagship hotel owned by Action Hotels is built on a long-term, 92-year lease plot of land held by Action Hotels and operated under AccorHotels' 4-star Novotel brand. Situated in Melbourne's newly re-developed Conference & Exhibition Centre, it is perfectly located to service both business and leisure travellers with quality affordable accommodation. The Melbourne Convention and Exhibition Centre is the largest convention centre in the southern hemisphere and currently accommodates over 5,500 delegates, hosting over 1,030 events and attracting more than 680,000 attendees, with 220 events already confirmed for the new expansion space, commencing mid-2018.”

The hotel is already proving to be in high demand with better than expected advance bookings  of over AUS$3.5m.

FYDec18E rev $52.65m and $11m pre-tax loss.

 

Watkin Jones (LON:WJG) 183.6p £468.7m

The “UK developer and constructor of multi occupancy property assets, with a focus on the student accommodation and build to rent sectors, confirms that the Group has achieved planning consent on Whitefriars Lane in Coventry for 778 student beds which will be delivered ahead of the start of the 2020/21 academic year.

In addition, the Group has secured, subject to satisfactory planning, a further site in Sheffield which is targeted to deliver in excess of 700 student beds ahead of the start of the 2021/22 academic year.  The growing momentum within the Group's student accommodation development business has led to the student accommodation development pipeline exceeding 9,800 beds with over 8,300 beds having received planning consent.  

All the developments due for delivery ahead of the 2018/19 academic year have been forward sold.  Five of the seven schemes scheduled to be delivered ahead of the 2019/20 academic year have been forward sold, with the remainder now having received planning consent.”

FYSep18E rev  £342.17m and £47.43m PBT.

 

MedaPhor (LON:MED) 10.5p £9.52m

MedaPhor, the intelligent ultrasound software and simulation company, announced its preliminary results for the year ended 31 Dec 2017, a pivotal year where the Company expanded into the larger clinical ultrasound software market.

Financial highlights

Revenues increased 27% to £4.2m (2016: £3.3m). North America sales double to £1.7m

Rest of World sales up 44% to £1.8m, with 83% growth for sales into China

Raised £5.4m net of costs by way of placing of shares

Year-end cash at £4.3m (2016: £1.8m)

Operational highlights

Acquired Intelligent Ultrasound Limited bringing artificial intelligence expertise to the Group

Won UK Government grant of £0.5m for NeedleGuide development

Post year-end events

First pilot of artificial intelligence-based software in UK hospital

Commenced NeedleGuide development

Launched Bodyworks Eve, our third simulator platform, aimed at the Emergency Medicine market

 

Microsaic Systems (LON:MSYS) 2.1p £3.8m

The “developer of point of need mass spectrometry instruments,  announced a commercial contract with UK based technology and innovation centre, the Centre for Process Innovation (CPI).

The project will focus on examining the potential of the Microsaic Mass Spectrometry (MS) offering as an online, deployable tool for the elucidation of biopharmaceutical or biologic structure during the manufacturing or bioprocessing workflow.

Microsaic's technology is a powerful point of use analysis tool which can be integrated into complex manufacturing workflows, which has the potential to be utilised in upstream cell media, or downstream biologic purification. A typical workflow could benefit from real-time data to drive production optimisation, ensure process control compliance, and reduce risk for the final product.”

 

SDX Energy (LON:SDX) 49.5p £101.22m

The “North Africa focused oil and gas company, is pleased to announce that the SAH-2 well on the Sebou permit (SDX 75% working interest) in Morocco has been completed and tested at a restricted rate on a 40/64" choke. The well achieved an average flow rate of conventional natural gas of 12.9 million standard cubic feet per day, with a maximum flow rate during this test of 13.5 MMscf/ d.  The well will now be shut in for several days for a pressure build-up after which it will be connected to the local infrastructure and placed on test production.

In addition, the LNB-1 well on the Lalla Mimouna permit (SDX 75% working interest) in Morocco has been spud.  LNB-1 is the eighth well in the Company's nine well campaign in Morocco, and the first of two remaining exploration commitment wells to be drilled on the permit in 2018. The well is anticipated to take between 15-20 days to drill and if successful it will be completed, flow tested and connected to existing infrastructure.”

 

4d pharma (LON:DDDD) 133.5p £87.4m

The “pharmaceutical company focusing on the development of live biotherapeutics, provides the following update in relation to the development of its lead oncology candidate, MRx0518. MRx0518 is a single strain bacterial Live Biotherapeutic Product (LBP), isolated and purified from a healthy human faecal sample, that has been shown to have immune-stimulatory characteristics and activity in a number of pre-clinical cancer models. Following a successful development programme at the Company's own GMP production plant, plans are at an advanced stage to open clinical studies in the UK and the US in the near future. 

Data will be presented today at the Microbiome R&D and Business Collaboration Forum, Rotterdam by 4D's Chief Executive Officer, Duncan Peyton, identifying key aspects of the mode of action of MRx0518.  Research carried out by 4D has identified a specific component of the bacteria, flaA, that plays a key role in the activity of MRx0518 by stimulating pathways that are known to be associated with the body's response to cancer.”

 

Beeks Financial Cloud Group (LON:BKS) 59.5p £29.24m

The cloud computing and connectivity provider for financial markets,  announced entry into the cryptocurrency market via a collaboration with Gemini Trust Company, LLC a next-generation digital asset exchange and custodian. Gemini is a licensed digital asset exchange and custodian built for both individuals and institutions. As a New York trust company regulated by the New York State Department of Financial Services (NYSDFS), Gemini is a fiduciary and is therefore subject to the capital reserve requirements, cybersecurity requirements, and banking compliance standards set forth by the NYSDFS and the New York Banking Law (NYBL).”   Via this new collaboration, Beeks can provide direct connectivity to Gemini via the Beeks Cloud, allowing Beeks' clients who are existing clients of Gemini to source and trade Bitcoin &Ethereum legitimately and securely. FYJun18E rev £6.2m, PBT £1.2m.

 

Brave Bison (LON:BBSN) 0.85p £4.9m

FYDec17  results from the e social video company. Revenue decreased by 48% to £9.1m (2016: £17.7m). £5.7m of this was due to a low margin advertising revenue product that was terminated by the Company in Q1 2017.

Fee Based Services revenues were impacted by loss of two major clients in Q4 2016.

CEO Claire Hungate appointed Q3 2017, prompting a strategic shift in the Company's focus to drive the Company towards profitability - gearing Brave Bison for growth in 2018.

EBITDA loss reduced by 51% to £1.7m £4.8m cash at the year end .

Analysis and strategy completed in order to launch a portfolio of new owned & operated channels in early Summer 2018.

 

The Group continues to trade in line with management expectations. We could see no forecasts. 

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use